INTEGRATED EXPRESSION PROFILING CHARACTERIZES BIOLOGICAL HETEROGENEITY IN REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND THE RISK OF RICHTER TRANSFORMATION
EHA Learning Center, Johannes Bloehdorn, 214581
THE DIALOG BETWEEN MANTLE CELL LYMPHOMA AND MONOCYTES/MACROPHAGES CAN BE DISRUPTED BY BTK INHIBITION AND MONITORED THROUGH CD163 MODULATION IN VIVO
EHA Learning Center, Antonin Papin, 214645
MYD88 CONSTITUTIVE ACTIVATION IS DIRECTLY ABLE TO INDUCE INDOLENT LYMPHOPLASMACYTIC LYMPHOMA WITH MONOCLONAL IGM PEAK SECRETION IN 1 YEAR OLD MICE: A MODEL FOR WALDENSTROM'S MACROGLOBULINEMIA
EHA Learning Center, Christelle Vincent-Fabert, 214646
CELL OF ORIGIN AND GENOMIC PROFILE OF PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA DETERMINED USING THE NANOSTRING LST ASSAY AND ULTRA DEEP TARGETED NEXT GENERATION SEQUENCING
EHA Learning Center, Csaba Bödör, 214647
MOLECULAR PROFILE REFINES THE MRD-BASED PROGNOSTIC ASSESSMENT IN ADULTS WITH PHILADELPHIA NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Jordi Ribera, 215245
TCR ALPHA GENE REARRANGEMENTS AS A NEW TYPE OF CLONAL MARKERS IN PEDIATRIC T-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Alexander Komkov, 215246
THE PROGNOSIS FOR PATIENTS WITH PHILADELPHIA CHROMOSOME POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA WHO WERE INELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION IN THE TKI ERA.
EHA Learning Center, Akio Shigematsu, 215262
ENHANCING MANAGEMENT OF PH+ ALL BY MONITORING WITH AN ANALYTICALLY VALIDATED MULTIPLEX ASSAY FOR BCR-ABL1 MINOR BREAKPOINT (E1A2) WITH HIGHLY SENSITIVE DETECTION OF 1:40,000 (0.0025% OR 4.6 LOGS)
EHA Learning Center, Justin Brown, 215264
CLINICAL AND BIOLOGICAL CHARACTERISTICS OF TWO DISTINCT T(16;21) FUSIONS IN PEDIATRIC ACUTE MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS BY THE I-BFM STUDY GROUP
EHA Learning Center, Sanne Noort, 215279
NUP98-KDM5A FUSION GENE IS AN INDEPENDENT PREDICTOR OF POOR PROGNOSIS WITH A DISTINCT HOX GENE EXPRESSION PATTERN
EHA Learning Center, Sanne Noort, 215280
SINGLE CELL SIGNALING PHARMACODYNAMICS AND CLONAL EVOLUTION IN A PHASE 1/2 CLINICAL TRIAL OF SELECTIVE AXL INHIBITOR BEMCENTINIB (BGB324) IN R/R ACUTE MYELOID LEUKEMIA AND MYELODYSPLASTIC SYNDROME
EHA Learning Center, Monica Hellesøy, 215296
FURTHER EVIDENCE FOR GPR56, BUT NOT CLL-1 (CLEC12A) AS A MARKER FOR LEUKEMIC STEM CELLS IN CD34-POSITIVE ACUTE MYELOID LEUKEMIA
EHA Learning Center, Albert Wölfler, 215297
IDENTIFYING A GENETICALLY DEFINED RISK GROUP OF PEDIATRIC AML PATIENTS THAT CANNOT BE RESCUED AT ALL AFTER THE FAILURE OF THE FIRST LINE TREATMENT
EHA Learning Center, Naghmeh Niktoreh Mofrad, 215312
A PHASE II STUDY OF THE AURORA A KINASE INHIBITOR ALISERTIB COMBINED WITH 7+3 INDUCTION CHEMOTHERAPY IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA
EHA Learning Center, Amir Fathi, 215313
IMPACT OF BCL2 AND ABCG2 OVEREXPRESSION IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Mario Tiribelli, 215328
ABSOLUTE LYMPHOCYTE COUNT RECOVERY AFTER INDUCTION REMISSION THERAPY IS A STRONG PREDICTOR OF OVERALL SURVIVAL IN ADULT ACUTE MYELOID LEUKAEMIA
EHA Learning Center, Joana Infante, 215329
GENETIC EVIDENCE IMPLYING THE COMMON PRECURSOR CELLS FOR PRIMARY AND EXTRA-CENTRAL NERVOUS SYSTEM RELAPSED TUMORS IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA
EHA Learning Center, Keiichiro Hattori, 215344
REAL-TIME CELL-OF-ORIGIN SUBTYPE IDENTIFICATION BY GENE EXPRESSION PROFILING IN PATIENTS WITH ABC-TYPE DLBCL IN THE PHASE III TRIAL OF LENALIDOMIDE + R-CHOP (R2-CHOP) VS PLACEBO + R-CHOP (ROBUST)
EHA Learning Center, Annalisa Chiappella, 215345
LIPOSOMAL DOXORUBICIN IN AGGRESSIVE B CELL LYMPHOMA SHOWS SIMILAR EFFICACY TO THE CONVENTIONAL FORMULATION: LONG TERM RESULTS FROM A RETROSPECTIVE COHORT STUDY
EHA Learning Center, Ana García-Noblejas, 215360
CLINICAL CHARACTERISTICS AND PROGNOSTIC FACTORS OF HEMOPHAGOCYTIC SYNDROME IN ADULT PATIENTS: A RETROSPECTIVE SINGLE-CENTER STUDY FROM SINGAPORE
EHA Learning Center, Shin-Yeu ONG, 215361
IDIOPATHIC NEUTROPENIA OF INFANCY: DATA FROM THE ITALIAN NEUTROPENIA REGISTRY
EHA Learning Center, Piero Farruggia, 215376
DYNAMICS OF CMV AND EBV LOADS AFTER IMMUNOSUPPRESSIVE TREATMENT WITH RABBIT ATG AND CYCLOSPORINE IN ADULT APLASTIC ANEMIA: A PROSPECTIVE OBSERVATIONAL STUDY
EHA Learning Center, Jong Wook Lee, 215377
PEMBROLIZUMAB (PEM) ACTIVITY IN CLL IS IMMUNE TO TUMOR MICROENVIRONMENTAL (TME) STIMULI
EHA Learning Center, Fortunato Morabito, 215392
DUAL MTOR KINASE INHIBITORS SYNERGIZE WITH IBRUTINIB TO INDUCE CLL APOPTOSIS, AND OVERCOME BCR- AND STROMAL-MEDIATED SURVIVAL ADVANTAGES CONFERRED IN THE MICROENVIRONMENT
EHA Learning Center, Michael Moles, 215393
EVALUATION OF THE INCIDENCE, RISK FACTORS, AND MANAGEMENT OF HYPERTENSION IN PATIENTS RECEIVING IBRUTINIB FOR HEMATOLOGIC MALIGNANCIES
EHA Learning Center, Farrukh Awan, 215409
EVALUATION OF THE CLL-IPI IN PREVIOUSLY UNTREATED CLL PATIENTS RECEIVING CHEMO-IMMUNOTHERAPY AS FIRST-LINE TREATMENT: ANALYSIS OF 845 CASES.
EHA Learning Center, Massimo GENTILE, 215410
ASXL1 MUTATIONS ARE FREQUENT IN CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO TYROSINE KINASE INHIBITORS BUT NOT IN PATIENTS WITH OPTIMAL RESPONSE
EHA Learning Center, Marcin MACHNICKI, 215425
THE UNCOVERING OF A BCR-ABL1 TYROSINE KINASE-INDEPENDENT SIGNATURE REVEALS NEW POTENTIAL THERAPEUTIC TARGETS IN CHRONIC MYELOID LEUKAEMIA STEM CELLS
EHA Learning Center, Mhairi Copland, 215426
CROSS-INTOLERANCE WITH BOSUTINIB AFTER PRIOR TYROSINE KINASE INHIBITORS IN PATIENTS WITH PHILADELPHIA CHROMOSOME–POSITIVE LEUKEMIA: PHASE 1/2 STUDY UPDATE
EHA Learning Center, Jorge Cortes, 215441
CHRONIC MYELOID LEUKEMIA ITALIAN MULTICENTER OBSERVATIONAL STUDY (CML-IT-MOS): ANALYSIS OF CLINICAL CHARACTERISTICS OF 1330 CML PATIENTS TREATED IN REAL-LIFE IN 66 ITALIAN CENTERS OF THE GIMEMA GROUP
EHA Learning Center, Giorgina Specchia, 215442
SYNERGISTIC ANTITUMORAL EFFICACY OF A NOVEL REPLICATIVE ADENOVIRUS SG611-PDCD5 AND DAUNORUBICIN IN HUMAN LEUKEMIC CELLS
EHA Learning Center, Ya-Lan Zhou, 215458
NOVEL RNA CONSTRUCT INCREASES PERFORIN AND GRANZYME B IN NATURAL KILLER AND CYTOTOXIC T CELLS
EHA Learning Center, Arnika Wagner, 215459
ENHANCING BONE MARROW TREPHINE BIOPSY ANALYZES: DEFINING PEDIATRIC LYMPHOID SUBPOPULATION REFEERENCE RANGES BY AUTOMATED ENUMERATION
EHA Learning Center, Jacques Malherbe, 215474
ROLE OF SPHINGOLIPID SIGNALING IN HEMATOPOIETIC STEM AND PROGENITOR CELL MOBILIZATION
EHA Learning Center, Alexander Carpinteiro, 215475
EARLY INTERIM POSITRON EMISSION TOMOGRAPHY (PET) EVALUATION OF RESPONSE AFTER 2 ABVD CYCLES IN ADVANCED HODGIN LYMPHOMA (HL): 8-YEAR EXPERIENCE IN HELLENIC DEPARTMENTS – CONCLUSIONS AND LIMITATIONS
EHA Learning Center, Theodoros Vassilakopoulos, 215490
THE IMPACT OF CXCR4 MUTATION SUBTYPES IN THE RESPONSE AND PROGRESSION-FREE SURVIVAL OF PATIENTS WITH WALDENSTROM MACROGLOBULINEMIA TREATED WITH IBRUTINIB
EHA Learning Center, Jorge Castillo, 215491
PEDIATRIC INTENSIVE CARE ADMISSIONS IN CHILDREN WITH ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Learning Center, Melpomeni Rompola, 215507
OUTCOME OF HIGH RISK FEBRILE NEUTROPENIC PATIENTS WITH GUT COLONIZATION WITH CARBAPENEM RESISTANT ENTEROBACTERIACEAE(CRE) IN SURVEILLANCE CULTURES "
EHA Learning Center, Sweta Lunkad, 215508
GENETIC STUDIES REVEAL NEW MUTATIONS IN THE CP GENE IN ACERULOPLASMINEMIA PATIENTS
EHA Learning Center, Giacomo Marchi, 215524
DIAGNOSIS OF HEREDITARY HAEMATOLOGICAL DISEASES USING NEXT GENERATION SEQUENCING PANELS
EHA Learning Center, Mayka Sanchez Fernandez, 215525
MDS WITH P53 DYSFUNCTION: A NEW PROGNOSTIC AND PREDICTIVE CATEGORY. A STUDY FROM THE ITALIAN MDS CLINICAL NETWORK
EHA Learning Center, Marianna rossi, 215539
A FLOW-CYTOMETRY SCORING SYSTEM OF ABNORMAL GRANULOCYTES AND MONOCYTES MATURATION PROFILES FOR DIAGNOSIS OF MYELODYSPLASTIC SYNDROMES
EHA Learning Center, Nicolas chapuis, 215540
ALTERED CARBONYLATION PATTERN IN MYELODISPLASTIC SYNDROMES
EHA Learning Center, Alba Rodríguez García, 215541
INTENSIVE CHEMOTHERAPY (IC) IS MORE EFFECTIVE THAN HYPOMETHYLATING AGENTS (HMA) FOR THE TREATMENT OF YOUNGER PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) AND ELEVATED BONE MARROW BLASTS
EHA Learning Center, Paola Strati, 215555
FETAL HEMOGLOBIN INDUCTION DURING DECITABINE TREATMENT OF ELDERLY MDS/AML PATIENTS: A POTENTIAL DYNAMIC BIOMARKER FOR OUTCOME
EHA Learning Center, Julia Stomper, 215556
CLINICAL IMPACT ON THE THERAPEUTIC STRATEGY ADAPTED TO THE MUTATIONAL PROFILE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME ASSOCIATED WITH DEL(5Q)
EHA Learning Center, Carolina Alarcón-Payer, 215557
ARGININE DEPRIVATION SUSTAINS PLASMA CELL FITNESS AND BIOENERGETICS IN MULTIPLE MYELOMA
EHA Learning Center, Alessandra Romano, 215572
DEMETHYLATION SENSITISES T(4;14) MULTIPLE MYELOMA TO RAS-MAPK PATHWAY INHIBITION
EHA Learning Center, Jay Hocking, 215573
CD96 (TACTILE) NEGATIVELY REGULATES THE CYTOTOXIC FUNCTIONS OF NATURAL KILLER CELLS AGAINST MULTIPLE MYELOMA
EHA Learning Center, Michael O'Dwyer, 215574
CIRCULATING SOLUBLE UROKINASE-TYPE PLASMINOGEN ACTIVATOR RECEPTOR LEVELS REFLECTS RENAL FUNCTION IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA WHO ARE TREATED WITH BORTEZOMIB-BASED THERAPY
EHA Learning Center, Evangelos Terpos, 215588
PAN-ANTI-FGF-BASED THERAPY AS A NOVEL THERAPEUTIC INTERVENTION IN WALDENSTROM’S MACROGLOBULINEMIA
EHA Learning Center, Antonio Sacco, 215589
EVALUATION OF THE ACTIVITY OF IMIDS IN MM PROLIFERATING CELLS
EHA Learning Center, Joan Ballesteros, 215590
EVALUATION OF MINIMAL RESIDUAL DISEASE USING NEXT GENERATION FLOW CYTOMETRY IN PATIENTS WITH LIGHT CHAIN (AL) AMYLOIDOSIS
EHA Learning Center, Ioannis Kostopoulos, 215604
EARLY LIGHT CHAIN KINETICS AND DEPTH/DURATION OF HEMATOLOGIC RESPONSES TO DARATUMUMAB IN PREVIOUSLY TREATED LIGHT CHAIN AMYLOIDOSIS
EHA Learning Center, Gregory Kaufman, 215605
EFFICACY AND TOLERABILITY OF DARATUMUMAB AFTER ALLOGENEIC TRANSPLANTATION FOR HEAVILY TREATED MULTIPLE MYELOMA.
EHA Learning Center, Ana González Rodríguez, 215606
PREDICTORS OF HEMATOLOGIC AND ORGAN RESPONSE IN AL AMYLOIDOSIS
EHA Learning Center, Giovanni Palladini, 215620
IXAZOMIB IN COMBINATION WITH THALIDOMIDE AND DEXAMETHASONE FOR INDUCTION AND IXAZOMIB MAINTENANCE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Heinz Ludwig, 215621
SELINEXOR COMBINED WITH LOW DOSE BORTEZOMIB AND DEXAMETHASONE (SVD) INDUCES A HIGH RESPONSE RATE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM)
EHA Learning Center, Nizar Bahlis, 215622
RANDOMIZED CLINICAL TRIAL (RCT) REPRESENTATIVENESS & OUTCOMES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REAL WORLD (RW) PATIENTS: COMPARISON OF ASPIRE, TOURMALINE-MM1, POLLUX, & ELOQUENT RCTS
EHA Learning Center, Dorothy Romanus, 215636
PHARMACOKINETIC EVALUATION OF TEST DOSE PREDICTIONS OF HIGH DOSE MELPHALAN EXPOSURE IN PATIENTS WITH MULTIPLE MYELOMA.
EHA Learning Center, Judith Trotman, 215637
A PHASE II STUDY OF SELINEXOR(KPT-330) COMBINED WITH BORTEZOMIB AND DEXAMETHASONE (SVD) FOR INDUCTION AND CONSOLIDATION FOR PATIENTS WITH PROGRESSIVE OR REFRACTORY MULTIPLE MYELOMA: THE SELVEDEX TRIAL
EHA Learning Center, A Broijl, 215638
MYELOID AND LYMPHOID NEOPLASMS ASSOCIATED WITH PDGFRA AND PDGFRB REARRANGEMENTS: CLINICAL CORRELATES AND SURVIVAL OUTCOMES.
EHA Learning Center, Abhishek Mangaonkar, 215652
ASSESSING SERUM ALBUMIN CONCENTRATION, LYMPHOCYTE COUNT AND PROGNOSTIC NUTRITIONAL INDEX MIGHT IMPROVE PROGNOSTICATION IN PATIENTS WITH MYELOFIBROSIS
EHA Learning Center, Marko Lucijanic, 215653
LONG-TERM OUTCOME OF PATIENTS WITH SPLANCHNIC VEIN THROMBOSIS AND MYELOPROLIFERATIVE NEOPLASMS: A SINGLE CENTER EXPERIENCE
EHA Learning Center, Danijela Lekovic, 215654
MANAGEMENT AND OUTCOME OF PATIENTS DIAGNOSED WITH POLYCYTHEMIA VERA IN YOUNG AGE
EHA Learning Center, Giulia Bogoni, 215668
RUXOLITINIB IN MYELOFIBROSIS: A MULTICENTRE EXPERIENCE IN ENGLAND, NORTHERN IRELAND AND WALES
EHA Learning Center, James Russell, 215669
TREATMENT STRATEGIES FOR POLYCYTHEMIA VERA: OBSERVATIONS IN A DUTCH ‘REAL-WORLD’ COHORT STUDY
EHA Learning Center, Peter Westerweel, 215670
PROTEIN KINASE CK1 ΑLPHA SUSTAINS MANTLE CELL LYMPHOMA SURVIVAL BY IMPINGING ON BCR-LINKED SIGNALING PATHWAYS
EHA Learning Center, Sabrina Manni, 215685
WEE1 INHIBITION ENHANCES ANTI-APOPTOTIC DEPENDENCY OF DIFFUSE LARGE B-CELL LYMPHOMA CAUSED BY CELL CYCLE ARREST AND DNA DAMAGE INDUCTION
EHA Learning Center, Mathilde de Jong, 215686
INFLUENCE OF PLASMA EBV LOAD ON PROGNOSIS OF HIV-RELATED LYMPHOMAS
EHA Learning Center, Jose-Tomas Navarro, 215687
INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISM IN EGYPTIAN CHILDREN AND ADOLESCENTS WITH IMMUNE THROMBOCYTOPENIA: ASSOCIATION WITH DISEASE SUSCEPTIBILITY, RESPONSE TO THERAPY AND OUTCOME
EHA Learning Center, Mohammed Mostafa Kamel Al-tawil, 215702
CLINICAL CHARACTERISTICS AND TREATMENT COURSES FOR CYTOMEGALOVIRUS-ASSOCIATED THROMBOCYTOPENIA IN IMMUNOCOMPETENT CHILDREN AFTER NEONATAL PERIOD
EHA Learning Center, Ye Jee Shim, 215703
RAISED EXPRESSION OF APRIL IN THE PLATELET WITH IMMUNE THROMBOCYTOPENIA AND ITS CLINICAL IMPLICATIONS
EHA Learning Center, Yunfeng Hao, 215704
QUALITY OF LIFE IN ADVANCED-STAGE,ASYMPTOMATIC,NON-BULKY FOLLICULAR LYMPHOMA TREATED WITH RITUXIMAB SHOWS SIGNIFICANT IMPROVEMENT COMPARED WITH WATCHFUL-WAITING: PHASE 3 RANDOMISED INTERNATIONAL STUDY
EHA Learning Center, Maria A V Marzolini, 215719
HOW TO IDENTIFY PATIENTS WITH MALIGNANT HEMOPATHIES WHO DON’T BENEFIT FROM STANDARD DOSE CHEMOTHERAPY
EHA Learning Center, Stéphanie Dubruille, 215720
THE ROLE OF MENTAL AND BEHAVIORAL DISORDERS IN LEUKEMIA PREDISPOSITION: A NATIONWIDE CASE-CONTROL STUDY
EHA Learning Center, Hanna Moisander-Joyce, 215721
COST PER MEDIAN MONTH OF PROGRESSION‐FREE SURVIVAL FOR DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE COMPARED WITH CARFILZOMIB PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Eric Maiese, 215735
EFFICACY AND SAFETY OF FACILITATED SUBCUTANEOUS IGG ADMINISTRATION IN PATIENTS WITH SECONDARY IMMUNODEFICIENCY DUE TO HEMATOLOGICAL MALIGNANCIES. A SINGLE-CENTER RETROSPECTIVE ANALYSIS.
EHA Learning Center, Maria Dimou, 215736
IMPACT OF LOW GRADE ADVERSE EVENTS OF TYROSINE KINASE INHIBITORS ON THE QUALITY OF LIFE OF PATIENTS TREATED FOR CHRONIC MYELOID LEUKEMIA
EHA Learning Center, S.M.Amine BENLAZAR, 215737
SIMILAR OUTCOMES OF REDUCED INTENSITY HAPLOIDENTICAL TRANSPLANTATION WHEN COMPARED TO MATCHED UNRELATED DONOR TRANSPLANT IN DIFFUSE LARGE B CELL LYMPHOMA. A JOINT ANALYSIS FROM CIBMTR-LC & EBMT-LWP.
EHA Learning Center, Anna Sureda, 215752
TARGETING EXPANDED GUT HOMING EFFECTOR T CELL LINEAGES IN ACUTE INTESTINAL GRAFT VERSUS HOST DISEASE: IMPLICATIONS FOR VEDOLIZUMAB
EHA Learning Center, Varun Mehra, 215753
ELTROMBOPAG TO IMPROVE PLATELET RECOVERY IN HAPLOIDENTICAL STEM CELL TRANSPLANTS (HAPLO-SCT): RESULTS OF A PHASE II TRIALPLUS A COMPARISON TO CONTROL PATIENTS
EHA Learning Center, Uday Popat, 215754
ACUTE INTESTINAL GRAFT-VERSUS-HOST DISEASE AMONG PATIENTS UNDERGOING ALLOGENEIC CELL TRANSPLANT FOR HEMATOLOGICAL MALIGNANCY IN THE UNITED STATES: A RETROSPECTIVE CLAIMS DATABASE ANALYSIS
EHA Learning Center, Aliki Taylor, 215768
ALLOGENEIC HEMATOPOIETIC STEM CELLS TRANSPLANTATION FOR NON-HODGKIN’S LYMPHOMA IN SWITZERLAND. 30 YEARS OF EXPERIENCE 1985-2017.
EHA Learning Center, Stavroula Masouridi-Levrat, 215769
PHASE 2, OPEN-LABEL STUDY OF DEFIBROTIDE FOR PREVENTION OF ACUTE GVHD FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT)
EHA Learning Center, Selim Corbacioglu, 215770
THREE MONTH FULL WHOLE BLOOD AND MIXED T CELL CHIMERISM IS ASSOCIATED WITH SUPERIOR OUTCOMES IN REDUCED-INTENSITY ALEMTUZUMAB-BASED ALLOGENEIC STEM CELL TRANSPLANTS FOR HAEMATOLOGICAL MALIGNANCIES
EHA Learning Center, Alexandros Kanellopoulos, 215784
OUTCOMES OF SECOND ALLOGENEIC STEM CELL TRANSPLANTATION FOR RELAPSE OF HEMATOLOGICAL DISEASES OR GRAFT FAILURE: A SINGLE-CENTRE EXPERIENCE
EHA Learning Center, Monica Poiani, 215785
CLOFARABINE- BASED CYTOREDUCTIVE TREATMENT FOLLOWED BY MYELOABLATIVE CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANTATION IN CHILDREN WITH HIGH-RISK, RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES.
EHA Learning Center, DIEGO MEDINA VALENCIA, 215786
THALASSEMIA PREVENTION PROGRAM IN DEVELOPING WORLD SCENARIO: 13 YEARS EXPERIENCE
EHA Learning Center, Kousar Perveen, 215800
ASSOCIATION OF VITAMIN D AND RETINOID X RECEPTORS EXPRESSION AND VITAMIN D BINDING PROTEIN VARIANTS WITH BONE DENSITY IN THALASSEMIA CHILDREN
EHA Learning Center, shaimaa sahmoud, 215801
NEW OCCURRENCES OF MACROSCOPIC MYOCARDIAL FIBROSIS IN THALASSEMIA AT LONG TERM BY MULTIPLE FOLLOW-UP
EHA Learning Center, Alessia Pepe, 215802
LABORATORY CRITERIA FOR THE DIAGNOSTIC RELIABILITY OF TESTS FOR DETECTION OF LUPUS ANTICOAGULANT IN PATIENTS WITH SUSPECTED ANTIPHOSPHOLIPID SYNDROME
EHA Learning Center, Valeriia Krasivska, 215817
THE COAGULATION SYSTEM FUNCTIONING IN PATIENTS WITH MYELOFIBROSIS
EHA Learning Center, Elizaveta Efremova, 215818
PLATELET MAPPING BY THROMBOELASTOGRAPHY- ASSESSMENT OF PLATELET INHIBITION SECONDARY TO ANTIPLATELET THERAPY AFTER PCI
EHA Learning Center, DIBYENDU DE, 215819
LENALIDOMIDE PLUS BENDAMUSTINE-RITUXIMAB DOES NOT OVERCOME THE ADVERSE IMPACT OF TP53 MUTATIONS IN MANTLE CELL LYMPHOMA
EHA Learning Center, Christian Winther Eskelund, 215897
HIGH RISK AGGRESSIVE B-CELL LYMPHOMAS IDENTIFIED BY FISH: A MULTICENTRIC RETROSPECTIVE STUDY FROM CENTERS OF THE FONDAZIONE ITALIANA LINFOMI
EHA Learning Center, Maria Chiara Tisi, 215898
GAU-PED STUDY: UPDATE ON RESULTS AND LONG-TERM OUTCOME OF PATIENTS WITH GAUCHER DISEASE DIAGNOSED THROUGH A PAEDIATRIC ALGORITHM
EHA Learning Center, William Morello, 215899
CYCLIN D1-MEDIATED GENE EXPRESSION DYSREGULATION IMPACTS MANTLE CELL LYMPHOMA PATHOGENESIS
EHA Learning Center, Silvia Beà Bobet, 215913
TPL2 KINASE HAS A TUMOR SUPPRESSIVE ROLE IN MYC-INDUCED LYMPHOMAGENESIS
EHA Learning Center, ELIAS STAGAKIS, 215914
INSUFFICIENT RECEPTOR EDITING LEADS TO DEFECTIVE B CELL CENTRAL TOLERANCE IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
EHA Learning Center, Zi Sheng, 215915

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings